Loading organizations...

§ Private Profile · Cambridge, MA, USA
Clinical-stage biopharma developing small molecule neuroprotective therapeutics for brain injuries and neurodegenerative diseases.
Astrocyte Pharmaceuticals is a clinical-stage biopharmaceutical company based in Groton, Connecticut, that develops proprietary small molecule therapeutics to treat acute brain injuries and neurodegenerative diseases. The organization focuses on neuroprotective drugs that selectively activate astrocytes to accelerate recovery for patients suffering from strokes, concussions, and traumatic brain injuries. Operating with a team of five employees, the pre-revenue biotech firm has secured over twenty-five million dollars in total capital funding from Boston Harbor Angels, Broadview Ventures, the National Institutes of Health, and the Department of Defense. The company recently initiated human Phase 1 clinical trials for its lead drug candidate, AST-004, following successful efficacy testing in various animal models. Astrocyte Pharmaceuticals was founded in August 2014 by researchers William Korinek, James Lechleiter, and Theodore Liston to advance these novel cerebroprotective therapies for brain injury patients worldwide.
Astrocyte Pharmaceuticals has raised $19.3M across 4 funding rounds.
Astrocyte Pharmaceuticals has raised $19.3M in total across 4 funding rounds.
Astrocyte Pharmaceuticals has raised $19.3M across 4 funding rounds. Most recently, it raised $6.0M Pre-Series B in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 18, 2023 | $6M Series A Plus | Gorka Fius | Howard Fillit, Boston Harbor Angels, DeepWork Capital, Life Science Angels, Mass Medical Angels, MID Atlantic BIO Angels, Navis VB Fund I, Sidecar Angels | Announced |
| May 1, 2021 | $6M Series A | Boston Harbor Angels, Good Growth Capital | DeepWork Capital, SAM Goldberger, Astia Angels, Band OF Angels, Berkeley Angel Network, CR, Dreamers Startup Ventures, Kyto Technology & Life Science, Life Science Angels, Mass Medical Angels, MID Atlantic BIO Angels, Portfolia, Reno Seed Fund, Sidecar Angels, Trend Investment Group, ZHI GAO Holding | Announced |
| Nov 1, 2020 | $5M Series A | — | DeepWork Capital | Announced |
| Jun 6, 2018 | $2.3M Seed Plus | JIN QI | Boston Harbor Angels, Mass Medical Angels, Nest.Bio Ventures, Sidecar Angels, ZHI GAO Holding | Announced |
Astrocyte Pharmaceuticals has raised $19.3M in total across 4 funding rounds.
Astrocyte Pharmaceuticals's investors include Gorka Fius, Howard Fillit, Boston Harbor Angels, DeepWork Capital, Life Science Angels, Mass Medical Angels, Mid Atlantic Bio Angels, Navis VB Fund I, SideCar Angels, Good Growth Capital, Sam Goldberger, Astia Angels.
Astrocyte Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel neuroprotective therapies by selectively activating astrocytes, the brain's most abundant support cells, to treat acute brain injuries and neurodegenerative diseases.[1][2][3] Its lead candidate, AST-004, a small-molecule adenosine A1/A3 receptor agonist, is administered intravenously within 24 hours of injury to limit neuronal damage from traumatic brain injury (TBI), concussion, stroke, or similar conditions, with an oral formulation in preclinical development for chronic use.[2][4] The company targets emergency responders and medical professionals serving patients with high unmet needs in brain injury care, where traditional neuron-focused therapies have failed, addressing problems like edema, glutamate excitotoxicity, oxidative stress, and cell death.[1][3] AST-004 is currently in Phase II human clinical trials for acute ischemic stroke and moderate-severe TBI, showing preclinical promise in reducing Alzheimer's disease plaques and supporting expansion into neurodegeneration.[4][5]
Astrocyte Pharmaceuticals emerged as a pioneering biotech focused on astrocytes after founders recognized their underappreciated role as "caretaker cells" in brain repair, distinct from prior neuron-centric approaches.[1][6] The company, described as a "new company" in a 2015 profile, was founded to advance small-molecule purinergic agonists that boost astrocyte energy production (via mitochondrial ATP) to heal damaged brains, building on emerging science highlighting glia cells' multifunctional repair roles.[3][5][6] Early traction came from preclinical models demonstrating lesion reduction in brain injury, leading to grants like one from the Alzheimer's Drug Discovery Foundation for AST-004's potential in Alzheimer's and chronic traumatic encephalopathy (CTE), linked to repetitive TBIs.[5] Headquartered in Groton, CT, with ties to Massachusetts biotech hubs, pivotal moments include launching Phase II trials for AST-004 and exploring oral formulations.[2][4]
Astrocyte Pharmaceuticals rides the glia-centric neuroscience trend, shifting from neuron-only models to astrocytes' roles in repair, synaptic support, blood-brain barrier maintenance, and inflammation control amid rising brain injury prevalence—leading global causes of death/disability.[3][5] Timing aligns with surging demand: TBIs from sports/military, strokes aging populations, and neurodegeneration epidemics (e.g., Alzheimer's projected to affect 13M+ Americans by 2050, costing billions).[5] Market forces favor it via biotech hubs like MassBio/BioCT, funding for innovative neuroprotection, and overlaps between acute injury therapies and chronic diseases like CTE/Alzheimer's from repetitive TBIs.[1][2][5] It influences the ecosystem by validating astrocytes as targets, potentially enabling first-in-class drugs where dozens of prior trials failed, accelerating glia research in pharma.[1][6]
Astrocyte's Phase II data could catalyze breakthroughs, with Phase III/NDA looming in 2-5 years if efficacy holds, expanding AST-004 to oral chronic use for Alzheimer's/CTE amid glia therapy momentum.[4][5] Trends like AI-driven drug discovery, personalized neurotherapeutics, and post-pandemic brain health focus will shape its path, potentially via partnerships or buyouts by big pharma seeking neuroprotection pipelines. Its influence may grow by proving astrocyte activation's versatility, redefining brain injury treatment from damage control to proactive repair—positioning it as a high-impact player in a market desperate for wins.